THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Thursday, August 06, 2020
Immunovia AB is extending their lung cancer detection program due to the recent results in lung cancer.
FREMONT, CA: Today Immunovia AB (publ) has announced that the results of the present study in lung cancer firmly endorses the development into the next stage of the detection procedure. With the latest capital raise, Immunovia is entirely financed to increase the process of discovery in lung cancer. The next level in the lung cancer program development is a study of a more significant unit of fresh lung cancer samples that best reflects the commercial environment.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Lung cancer is by far the primary source of cancer death among both men and women. Each year, maximum people die of lung cancer than other cancers like colon, breast, and prostate cancers combined. About 13% of the new versions are cancers are lung cancers. With the current lung cancer program, Immunovia intends to be the first to provide a prospect that will enhance the chances of survival with advanced detection of cancer.
“These results from lung cancer demonstrate that our powerful technology platform IMMray™ delivers significant robustness in lung cancer, which further validates our excitement about our platform that has the potential to revolutionize differential diagnosis for the early detection of many cancers,” stated Mats Grahn, CEO of Immunovia.
Overview of the Process in Lung Cancer Program
Presently, Immunovia’s lung cancer study is now at Step 5 of the discovery process. As previously it has been guided, the discovery procedure can often consist of numerous clinical studies that utilize the samples that have been collected from Immunovia’s growing KOL network before they started advancing to the development stage.
More in News